View Future GrowthCapsoVision 과거 순이익 실적과거 기준 점검 0/6CapsoVision 의 수입은 연평균 -28%의 비율로 감소해 온 반면, Medical Equipment 산업은 연평균 13.6%의 비율로 증가했습니다. 매출은 연평균 12.6%의 비율로 증가해 왔습니다.핵심 정보-28.00%순이익 성장률92.55%주당순이익(EPS) 성장률Medical Equipment 산업 성장률8.90%매출 성장률12.61%자기자본이익률-133.40%순이익률-198.87%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트공시 • May 02CapsoVision, Inc. to Report Q1, 2026 Results on May 14, 2026CapsoVision, Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026Reported Earnings • Mar 27Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: US$1.03 loss per share. Revenue: US$13.6m (up 15% from FY 2024). Net loss: US$25.3m (loss widened 27% from FY 2024). Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.공시 • Mar 13CapsoVision, Inc. to Report Q4, 2025 Results on Mar 26, 2026CapsoVision, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026Reported Earnings • Nov 14Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: US$0.17 loss per share. Net loss: US$7.92m (flat on 3Q 2024). Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 36%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.공시 • Oct 31CapsoVision, Inc. to Report Q3, 2025 Results on Nov 13, 2025CapsoVision, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025Reported Earnings • Aug 19Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: US$2.02 loss per share. Net loss: US$4.63m (flat on 2Q 2024). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.모든 업데이트 보기Recent updatesNew Risk • May 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$24m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$24m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$24m net loss next year). Share price has been volatile over the past 3 months (14% average weekly change).New Risk • May 11New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$25m Forecast net loss in 1 year: US$23m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$23m net loss next year). Share price has been volatile over the past 3 months (14% average weekly change).공시 • May 02CapsoVision, Inc. to Report Q1, 2026 Results on May 14, 2026CapsoVision, Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026공시 • May 01CapsoVision, Inc., Annual General Meeting, Jun 11, 2026CapsoVision, Inc., Annual General Meeting, Jun 11, 2026.Major Estimate Revision • Apr 02Consensus revenue estimates decrease by 18%, EPS upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$19.2m to US$15.8m. EPS estimate increased from -US$0.49 to -US$0.48 per share. Medical Equipment industry in the US expected to see average net income growth of 12% next year. Consensus price target reaffirmed at US$10.50. Share price was steady at US$7.44 over the past week.Reported Earnings • Mar 27Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: US$1.03 loss per share. Revenue: US$13.6m (up 15% from FY 2024). Net loss: US$25.3m (loss widened 27% from FY 2024). Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.공시 • Mar 13CapsoVision, Inc. to Report Q4, 2025 Results on Mar 26, 2026CapsoVision, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026새로운 내러티브 • Feb 09AI Delays And Mounting R&D Costs Will Eventually Reward Capsule Endoscopy AdoptionCatalysts About CapsoVision CapsoVision develops wire free, cloud connected capsule endoscopy systems for gastrointestinal disease screening and diagnosis. What are the underlying business or industry changes driving this perspective?새로운 내러티브 • Jan 25Cloud And AI Capsule Endoscopy Will Reshape Long Term Prospects For This Undervalued GI PlayerCatalysts About CapsoVision CapsoVision develops cloud connected capsule endoscopy systems that use panoramic imaging and AI to support noninvasive gastrointestinal screening and diagnostics. What are the underlying business or industry changes driving this perspective?공시 • Jan 01CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®?CapsoVision, Inc. announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its proprietary AI-assisted module for CapsoCam Plus®?. The addition of this reading tool will improve the detection of clinically significant pathology, as well as reduce clinician review time. The Company intends for U.S. commercialization activities to commence after the FDA clearance. CapsoVision's CapsoCam Plus capsule endoscopy system is intended for visualization of the small bowel mucosa to detect abnormalities of the small bowel in adults and children aged two years and older. The Company believes that it is a more advanced capsule endoscopy solution compared to competitor systems, both in how it captures and presents images of the GI tract and the clinical workflow and patient experience that it enables.Board Change • Dec 31High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Julia Gouw was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$21m free cash flow). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (14% average weekly change).Reported Earnings • Nov 14Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: US$0.17 loss per share. Net loss: US$7.92m (flat on 3Q 2024). Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 36%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.공시 • Nov 11CapsoVision, Inc. Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening CapsuleCapsoVision, Inc. announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) on November 6, 2025 requesting Breakthrough Device Designation (BDD) to accelerate development of the Company's CapsoCam UGI capsule endoscopy system for use in early-stage pancreatic cancer detection. This submission represents an important milestone in CapsoVision's mission to expand its capsule-based diagnostics platform beyond the small bowel and address some of the most challenging diseases in gastroenterology. Pancreatic ductal adenocarcinoma the most common form of pancreatic cancer is among the fatal cancers worldwide, with a five-year survival rate of only 8%, largely because it is diagnosed at advanced stages that cannot be treated. Currently, no early screening tools are recommended to identify the disease at a treatable stage in the general population. Unlike traditional endoscopic or imaging procedures, CapsoCam UGI is completely non-invasive. Patients simply allow a pill-sized camera, eliminating the need for sedation, intubation, or recovery time, while enabling physicians to review detailed images through a secure, cloud-based system. The FDA's Breakthrough Devices Program is designed to expedite the development and review of technologies that may offer more effective diagnosis or treatment for life-threatening conditions where no adequate alternatives exist. If granted, the designation would allow CapsoVision to work closely with the FDA to accelerate development and shape upcoming clinical studies, leading the regulatory review process. Pancreatic cancer remains one of the most lethal malignancies, with a five- year survival rate of only 10%, a figure that has seen little improvement in decades. It is now the third leading cause of cancer-related death in the United States, despite accounting for just over 3% of all cancer cases. Early detection can improve survival more than fourteen-fold5, yet no non-invasive screening method for the general population is currently recommended. This underscores an urgent global need for innovative, patient-friendly diagnostic technologies that can visualize pancreatic abnormalities earlier, before symptoms emerging and while curative treatment is still possible.공시 • Nov 04+ 1 more updateCapsovision, Inc. Appoints David Garcia as Senior Vice President of Finance and Principal Accounting Officer, Effective November 3, 2025CapsoVision, Inc. announced the appointment of David Garcia as Senior Vice President of Finance, effective November 3, 2025. Mr. Garcia brings more than 20 years of financial leadership experience spanning corporate finance, capital markets, and strategic transactions. He joins CapsoVision after serving as Vice President of Financial Planning and Analysis at Matterport, Inc., where he helped lead its initial public offering and played a key role in the company's recent acquisition. His background also includes senior finance roles at View, Inc., Intelepeer Cloud Communications, and Align Technology, as well as earlier experience with Oracle and Deloitte. Mr. Garcia earned a Master of Business Administration in Finance from The Wharton School, University of Pennsylvania, and a Bachelor of Arts in Economics from Stanford University. Effective as of November 3, 2025, David Garcia, Senior VP of Finance of CapsoVision, Inc. (the “Company”), has been appointed by the board of directors of the Company (the “Board”) to serve as the Company’s principal financial officer and principal accounting officer. Mr. Garcia, age 51, has more than 20 years of financial leadership experience and most recently served as Vice President of Financial Planning and Analysis at Matterport, Inc. from October 2020 through October 2025.공시 • Oct 31CapsoVision, Inc. to Report Q3, 2025 Results on Nov 13, 2025CapsoVision, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025공시 • Sep 27CapsoVision, Inc. Announces Board ChangesOn September 22, 2025, Rebecca Petersen notified CapsoVision, Inc. (the Company") of her planned retirement as the Company's Senior Director of Clinical Affairs, effective October 15, 2025. Concurrently, the Company promoted Ms. Keri Jorgenson to Director of Clinical Operations and Ms. Jorgenson, together with the other members of the clinical operations team, will assume responsibility of the Company's clinical development operations and activities. The Company does not anticipate any disruption to its clinical development operations and activities during this transition. Ms. Jorgenson joined CapsoVision in March 2022 and most recently served as the Company's Senior Clinical Project Manager, working closely with Ms. Petersen and the Company's broad, experienced clinical operations team.공시 • Sep 04CapsoVision, Inc. Announces Step Down of Kevin Lundquist as Chief Financial Officer, Effective August 27, 2025Effective August 27, 2025, Kevin Lundquist has stepped down as Chief Financial Officer of CapsoVision, Inc. (the “Company”). The Company has begun the search to identify a successor. The Company and Mr. Lundquist have mutually agreed that Mr. Lundquist will be available to provide consulting assistance and transition support to the Company for up to six months, until February 28, 2026. In connection therewith, the Company and Mr. Lundquist will enter into a Consulting Agreement to take effect immediately (the “ Consulting Agreement ”).Reported Earnings • Aug 19Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: US$2.02 loss per share. Net loss: US$4.63m (flat on 2Q 2024). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.공시 • Aug 01CapsoVision, Inc. to Report Q2, 2025 Results on Aug 14, 2025CapsoVision, Inc. announced that they will report Q2, 2025 results After-Market on Aug 14, 2025공시 • Jul 02CapsoVision, Inc. has completed an IPO in the amount of $27.5 million.CapsoVision, Inc. has completed an IPO in the amount of $27.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,500,000 Price\Range: $5 Discount Per Security: $0.35 Transaction Features: Sponsor Backed OfferingBoard Change • Jun 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman Chen Tsai was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역CapsoVision가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:CV 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 2614-27142031 Dec 2514-25141830 Sep 2513-23141630 Jun 2513-20131431 Mar 2512-21131531 Dec 2412-20111531 Dec 2310-1189양질의 수익: CV 은(는) 현재 수익성이 없습니다.이익 마진 증가: CV는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 CV의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 CV의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: CV은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(14.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: CV는 현재 수익성이 없으므로 자본 수익률이 음수(-133.4%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 19:58종가2026/05/20 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CapsoVision, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bruce JacksonBenchmark CompanyJason WittesRoth Capital PartnersKyle BauserRoth Capital Partners
공시 • May 02CapsoVision, Inc. to Report Q1, 2026 Results on May 14, 2026CapsoVision, Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026
Reported Earnings • Mar 27Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: US$1.03 loss per share. Revenue: US$13.6m (up 15% from FY 2024). Net loss: US$25.3m (loss widened 27% from FY 2024). Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.
공시 • Mar 13CapsoVision, Inc. to Report Q4, 2025 Results on Mar 26, 2026CapsoVision, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026
Reported Earnings • Nov 14Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: US$0.17 loss per share. Net loss: US$7.92m (flat on 3Q 2024). Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 36%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.
공시 • Oct 31CapsoVision, Inc. to Report Q3, 2025 Results on Nov 13, 2025CapsoVision, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
Reported Earnings • Aug 19Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: US$2.02 loss per share. Net loss: US$4.63m (flat on 2Q 2024). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
New Risk • May 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$24m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$24m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$24m net loss next year). Share price has been volatile over the past 3 months (14% average weekly change).
New Risk • May 11New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$25m Forecast net loss in 1 year: US$23m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$23m net loss next year). Share price has been volatile over the past 3 months (14% average weekly change).
공시 • May 02CapsoVision, Inc. to Report Q1, 2026 Results on May 14, 2026CapsoVision, Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026
공시 • May 01CapsoVision, Inc., Annual General Meeting, Jun 11, 2026CapsoVision, Inc., Annual General Meeting, Jun 11, 2026.
Major Estimate Revision • Apr 02Consensus revenue estimates decrease by 18%, EPS upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$19.2m to US$15.8m. EPS estimate increased from -US$0.49 to -US$0.48 per share. Medical Equipment industry in the US expected to see average net income growth of 12% next year. Consensus price target reaffirmed at US$10.50. Share price was steady at US$7.44 over the past week.
Reported Earnings • Mar 27Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: US$1.03 loss per share. Revenue: US$13.6m (up 15% from FY 2024). Net loss: US$25.3m (loss widened 27% from FY 2024). Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.
공시 • Mar 13CapsoVision, Inc. to Report Q4, 2025 Results on Mar 26, 2026CapsoVision, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026
새로운 내러티브 • Feb 09AI Delays And Mounting R&D Costs Will Eventually Reward Capsule Endoscopy AdoptionCatalysts About CapsoVision CapsoVision develops wire free, cloud connected capsule endoscopy systems for gastrointestinal disease screening and diagnosis. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Jan 25Cloud And AI Capsule Endoscopy Will Reshape Long Term Prospects For This Undervalued GI PlayerCatalysts About CapsoVision CapsoVision develops cloud connected capsule endoscopy systems that use panoramic imaging and AI to support noninvasive gastrointestinal screening and diagnostics. What are the underlying business or industry changes driving this perspective?
공시 • Jan 01CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®?CapsoVision, Inc. announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its proprietary AI-assisted module for CapsoCam Plus®?. The addition of this reading tool will improve the detection of clinically significant pathology, as well as reduce clinician review time. The Company intends for U.S. commercialization activities to commence after the FDA clearance. CapsoVision's CapsoCam Plus capsule endoscopy system is intended for visualization of the small bowel mucosa to detect abnormalities of the small bowel in adults and children aged two years and older. The Company believes that it is a more advanced capsule endoscopy solution compared to competitor systems, both in how it captures and presents images of the GI tract and the clinical workflow and patient experience that it enables.
Board Change • Dec 31High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Julia Gouw was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$21m free cash flow). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (14% average weekly change).
Reported Earnings • Nov 14Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: US$0.17 loss per share. Net loss: US$7.92m (flat on 3Q 2024). Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 36%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.
공시 • Nov 11CapsoVision, Inc. Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening CapsuleCapsoVision, Inc. announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) on November 6, 2025 requesting Breakthrough Device Designation (BDD) to accelerate development of the Company's CapsoCam UGI capsule endoscopy system for use in early-stage pancreatic cancer detection. This submission represents an important milestone in CapsoVision's mission to expand its capsule-based diagnostics platform beyond the small bowel and address some of the most challenging diseases in gastroenterology. Pancreatic ductal adenocarcinoma the most common form of pancreatic cancer is among the fatal cancers worldwide, with a five-year survival rate of only 8%, largely because it is diagnosed at advanced stages that cannot be treated. Currently, no early screening tools are recommended to identify the disease at a treatable stage in the general population. Unlike traditional endoscopic or imaging procedures, CapsoCam UGI is completely non-invasive. Patients simply allow a pill-sized camera, eliminating the need for sedation, intubation, or recovery time, while enabling physicians to review detailed images through a secure, cloud-based system. The FDA's Breakthrough Devices Program is designed to expedite the development and review of technologies that may offer more effective diagnosis or treatment for life-threatening conditions where no adequate alternatives exist. If granted, the designation would allow CapsoVision to work closely with the FDA to accelerate development and shape upcoming clinical studies, leading the regulatory review process. Pancreatic cancer remains one of the most lethal malignancies, with a five- year survival rate of only 10%, a figure that has seen little improvement in decades. It is now the third leading cause of cancer-related death in the United States, despite accounting for just over 3% of all cancer cases. Early detection can improve survival more than fourteen-fold5, yet no non-invasive screening method for the general population is currently recommended. This underscores an urgent global need for innovative, patient-friendly diagnostic technologies that can visualize pancreatic abnormalities earlier, before symptoms emerging and while curative treatment is still possible.
공시 • Nov 04+ 1 more updateCapsovision, Inc. Appoints David Garcia as Senior Vice President of Finance and Principal Accounting Officer, Effective November 3, 2025CapsoVision, Inc. announced the appointment of David Garcia as Senior Vice President of Finance, effective November 3, 2025. Mr. Garcia brings more than 20 years of financial leadership experience spanning corporate finance, capital markets, and strategic transactions. He joins CapsoVision after serving as Vice President of Financial Planning and Analysis at Matterport, Inc., where he helped lead its initial public offering and played a key role in the company's recent acquisition. His background also includes senior finance roles at View, Inc., Intelepeer Cloud Communications, and Align Technology, as well as earlier experience with Oracle and Deloitte. Mr. Garcia earned a Master of Business Administration in Finance from The Wharton School, University of Pennsylvania, and a Bachelor of Arts in Economics from Stanford University. Effective as of November 3, 2025, David Garcia, Senior VP of Finance of CapsoVision, Inc. (the “Company”), has been appointed by the board of directors of the Company (the “Board”) to serve as the Company’s principal financial officer and principal accounting officer. Mr. Garcia, age 51, has more than 20 years of financial leadership experience and most recently served as Vice President of Financial Planning and Analysis at Matterport, Inc. from October 2020 through October 2025.
공시 • Oct 31CapsoVision, Inc. to Report Q3, 2025 Results on Nov 13, 2025CapsoVision, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
공시 • Sep 27CapsoVision, Inc. Announces Board ChangesOn September 22, 2025, Rebecca Petersen notified CapsoVision, Inc. (the Company") of her planned retirement as the Company's Senior Director of Clinical Affairs, effective October 15, 2025. Concurrently, the Company promoted Ms. Keri Jorgenson to Director of Clinical Operations and Ms. Jorgenson, together with the other members of the clinical operations team, will assume responsibility of the Company's clinical development operations and activities. The Company does not anticipate any disruption to its clinical development operations and activities during this transition. Ms. Jorgenson joined CapsoVision in March 2022 and most recently served as the Company's Senior Clinical Project Manager, working closely with Ms. Petersen and the Company's broad, experienced clinical operations team.
공시 • Sep 04CapsoVision, Inc. Announces Step Down of Kevin Lundquist as Chief Financial Officer, Effective August 27, 2025Effective August 27, 2025, Kevin Lundquist has stepped down as Chief Financial Officer of CapsoVision, Inc. (the “Company”). The Company has begun the search to identify a successor. The Company and Mr. Lundquist have mutually agreed that Mr. Lundquist will be available to provide consulting assistance and transition support to the Company for up to six months, until February 28, 2026. In connection therewith, the Company and Mr. Lundquist will enter into a Consulting Agreement to take effect immediately (the “ Consulting Agreement ”).
Reported Earnings • Aug 19Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: US$2.02 loss per share. Net loss: US$4.63m (flat on 2Q 2024). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
공시 • Aug 01CapsoVision, Inc. to Report Q2, 2025 Results on Aug 14, 2025CapsoVision, Inc. announced that they will report Q2, 2025 results After-Market on Aug 14, 2025
공시 • Jul 02CapsoVision, Inc. has completed an IPO in the amount of $27.5 million.CapsoVision, Inc. has completed an IPO in the amount of $27.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,500,000 Price\Range: $5 Discount Per Security: $0.35 Transaction Features: Sponsor Backed Offering
Board Change • Jun 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman Chen Tsai was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
